...
首页> 外文期刊>Chinese Journal of Chemistry >Discovery of Anti-SARS Coronavirus Drug Based on Molecular Docking and Database Screening
【24h】

Discovery of Anti-SARS Coronavirus Drug Based on Molecular Docking and Database Screening

机译:基于分子对接和数据库筛选的抗SARS冠状病毒药物的发现

获取原文
获取原文并翻译 | 示例

摘要

The active site of 3CL proteinase (3CL~(pro)) for coronavirus was identified by comparing the crystal structures of human and porcine coronavirus. The inhibitor of the main protein of rhinovirus (Ag7088) could bind with 3CL~(pro) of human coronavirus, then it was selected as the reference for molecular docking and database screening. The ligands from two databases were used to search potential lead structures with molecular docking. Several structures from natural products and ACD-SC databases were found to have lower binding free energy with 3CL~(pro) than that of Ag7088. These structures have similar hydrophobicity to Ag7088. They have complementary electrostatic potential and hydrogen bond acceptor and donor with 3CL~(pro), showing that the strategy of anti-SARS drug design based on molecular docking and database screening is feasible.
机译:通过比较人和猪冠状病毒的晶体结构,鉴定了3CL蛋白酶(3CL〜(pro))对冠状病毒的活性位点。鼻病毒的主要蛋白抑制剂(Ag7088)可以与人冠状病毒的3CL〜(pro)结合,因此被选作分子对接和数据库筛选的参考。来自两个数据库的配体用于通过分子对接搜索潜在的先导结构。发现来自天然产物和ACD-SC数据库的几种结构与3CL_(pro)的结合自由能低于Ag7088。这些结构具有与Ag7088相似的疏水性。它们具有与3CL〜(pro)互补的静电势和氢键受体和供体,表明基于分子对接和数据库筛选的抗SARS药物设计策略是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号